EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics today, reported financial results for the quarter ended March 31, 2022.
Benzinga ·